Recursion (@recursionpharma) 's Twitter Profile
Recursion

@recursionpharma

Decoding biology to radically improve lives. The industrial revolution of drug discovery is here.

ID: 2615770806

linkhttp://www.recursion.com calendar_today10-07-2014 16:41:56

3,3K Tweet

11,11K Followers

798 Following

Recursion (@recursionpharma) 's Twitter Profile Photo

A 2021 "Hack Week" idea led us to a new approach for gathering #data from #cells using #brightfield - a 17th century technique w/ powerful new possibilities thanks to #ml. Since brightfield does not perturb cells, scientists can examine multiple layers of biology on the same

A 2021 "Hack Week" idea led us to a new approach for gathering #data from #cells using #brightfield - a 17th century technique w/ powerful new possibilities thanks to #ml. Since  brightfield does not perturb cells, scientists can examine multiple layers of biology on the same
Recursion (@recursionpharma) 's Twitter Profile Photo

Since our earliest days, we’ve planned a sunrise hike to the top of #Utah’s Mt. Olympus, led by co-founder and CEO Chris Gibson. It begins in the wee hours of the morning, in darkness. The reward is a new perspective & shared connection with nature & one another. This year,

Since our earliest days, we’ve planned a sunrise hike to the top of #Utah’s Mt. Olympus, led by co-founder and CEO <a href="/RecursionChris/">Chris Gibson</a>. It begins in the wee hours of the morning, in darkness. The reward is a new perspective &amp; shared connection with nature &amp; one another. This year,
Recursion (@recursionpharma) 's Twitter Profile Photo

Announcing positive Phase 2 topline results for our first-in-disease treatment for cerebral cavernous malformation (#CCM) – the #AI drug discovery that launched our company. REC-994 met its primary endpoint of safety & tolerability & showed promising MRI-based secondary efficacy

Announcing positive Phase 2 topline results for our first-in-disease treatment for cerebral cavernous malformation (#CCM) – the #AI drug discovery that launched our company. REC-994 met its primary endpoint of safety &amp; tolerability &amp; showed promising MRI-based secondary efficacy
Recursion (@recursionpharma) 's Twitter Profile Photo

So much attention has been paid to improving & accelerating discovery – but what about the clinical side? At the Drug Discovery Innovation Forum (#DDIF) in Berlin Sept. 4-5, Karen Sayal, MB BChir, MRCP, FRCR, DPhil, will present on how we are applying our automated workflows to

So much attention has been paid to improving &amp; accelerating discovery – but what about the clinical side? At the Drug Discovery Innovation Forum (#DDIF) in Berlin Sept. 4-5, Karen Sayal, MB BChir, MRCP, FRCR, DPhil, will present on how we are applying our automated workflows to